Sirio Pharma Past Earnings Performance

Past criteria checks 5/6

Sirio Pharma has been growing earnings at an average annual rate of 7.4%, while the Personal Products industry saw earnings growing at 9.8% annually. Revenues have been growing at an average rate of 18.2% per year. Sirio Pharma's return on equity is 9%, and it has net margins of 8.2%.

Key information

7.4%

Earnings growth rate

4.1%

EPS growth rate

Personal Products Industry Growth	7.8%
Revenue growth rate	18.2%
Return on equity	9.0%
Net Margin	8.2%
Last Earnings Update	31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Sirio Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:300791 Revenue, expenses and earnings (CNY Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Mar 24	3,831	315	658	119
31 Dec 23	3,582	281	627	110
30 Sep 23	3,222	221	564	95
30 Jun 23	2,941	204	517	88
31 Mar 23	2,788	227	485	84
01 Jan 23	2,507	212	432	81
30 Sep 22	2,409	208	408	85
30 Jun 22	2,315	196	398	82
31 Mar 22	2,283	189	377	84
31 Dec 21	2,369	232	386	83
30 Sep 21	2,361	272	350	74
30 Jun 21	2,316	279	335	74
31 Mar 21	2,216	265	336	71
31 Dec 20	2,067	257	310	65
30 Sep 20	1,865	209	327	68
30 Jun 20	1,710	178	312	66
31 Mar 20	1,554	156	285	62
31 Dec 19	1,580	143	279	66
30 Sep 19	1,625	186	254	66
31 Dec 18	1,595	203	238	62
31 Dec 17	1,330	104	225	46
31 Dec 16	786	704	151	41

Quality Earnings: 300791 has high quality earnings.

Growing Profit Margin: 300791's current net profit margins (8.2%) are higher than last year (8.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 300791's earnings have grown by 7.4% per year over the past 5 years.

Accelerating Growth: 300791's earnings growth over the past year (38.6%) exceeds its 5-year average (7.4% per year).

Earnings vs Industry: 300791 earnings growth over the past year (38.6%) exceeded the Personal Products industry -0.2%.

Sirio Pharma Past Earnings Performance

Past criteria checks 5/6

Key information

Recent past performance updates

First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.16 in 1Q 2023)

Sirio Pharma Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Sirio Pharma Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.37 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.54 in 2Q 2022)

Sirio Pharma Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Recent updates

First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.16 in 1Q 2023)

Sirio Pharma Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Sirio Pharma Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.37 in 3Q 2022)

Investor sentiment improves as stock rises 17%

Second quarter 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.54 in 2Q 2022)

Sirio Pharma Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Sirio Pharma Co., Ltd. Announces Implementation of Cash Dividend for the Year 2022, Payable on June 07, 2023

Full year 2022 earnings released: EPS: CN¥1.18 (vs CN¥1.29 in FY 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.37 (vs CN¥0.30 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.54 (vs CN¥0.49 in 2Q 2021)

Now 23% undervalued

Now 20% undervalued

Sirio Pharma Co., Ltd. announced that it expects to receive CNY 1.35 billion in funding

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Sirio Pharma Co., Ltd. Announces Final Profit Distribution Plan for 2021 on A Shares, Payable on 23 May 2022

Less than half of directors are independent

Sirio Pharma Co., Ltd., Annual General Meeting, May 05, 2022

First quarter 2022 earnings released: EPS: CN¥0.08 (vs CN¥0.32 in 1Q 2021)

Now 23% undervalued after recent price drop

Sirio Pharma Co., Ltd. Announces the Profit Distribution Proposal for 2021

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.34 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.41 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sirio Pharma Co., Ltd. Approves Final Divided for 2020

Sirio Pharma Co., Ltd. Proposes Final Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥2.14 (vs CN¥1.46 in FY 2019)

New 90-day low: CN¥83.31

New 90-day high: CN¥113

Investor sentiment improved over the past week

New 90-day low: CN¥84.38

New 90-day low: CN¥86.60

Third quarter earnings released

Market bids up stock over the past week

New 90-day high - CN¥116

Earnings released

Sirio Pharma Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥99.91

Sirio Pharma Co., Ltd. announced a financing transaction

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta